An outpatient, dose-intense, intravenous cisplatin and oral etoposide regimen for the treatment of advanced, platinum-resistant ovarian cancer.
Authors
Morgan, Robert DavidClamp, Andrew R
Hasan, Jurjees
Mitchell, Claire L
Saunders, Geoff
Mescallado, Nerissa
Welch, Richard
Jayson, Gordon C
Affiliation
The Christie Hospital NHS Foundation Trust, Manchester, United KingdomIssue Date
2018-03
Metadata
Show full item recordAbstract
Advanced-stage, platinum-resistant, ovarian cancer can be treated with dose-intense chemotherapy; one such regimen includes intravenous cisplatin and oral etoposide. To minimize the toxicity associated with weekly cisplatin, pretreatment and posttreatment hydration is required, often necessitating inpatient, overnight admission. We report a shorter, within-day regimen for delivering weekly cisplatin.Citation
An outpatient, dose-intense, intravenous cisplatin and oral etoposide regimen for the treatment of advanced, platinum-resistant ovarian cancer. 2018, 28(3): 448-452 Int J Gynecol CancerJournal
International Journal of Gynecological CancerDOI
10.1097/IGC.0000000000001194PubMed ID
29466253Type
ArticleLanguage
enISSN
1525-1438ae974a485f413a2113503eed53cd6c53
10.1097/IGC.0000000000001194
Scopus Count
Collections
Related articles
- Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
- Authors: Miller AA, Herndon JE 2nd, Hollis DR, Ellerton J, Langleben A, Richards F 2nd, Green MR
- Issue date: 1995 Aug
- Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer.
- Authors: van der Burg ME, de Wit R, van Putten WL, Logmans A, Kruit WH, Stoter G, Verweij J
- Issue date: 2002 Jan 7
- Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
- Authors: Bruixola G, Domingo S, Díaz R, Caballero J, Palomar L, De La Cueva H, Santaballa A
- Issue date: 2015 Feb
- Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
- Authors: van Rijswijk RE, Hoekman K, Burger CW, Verheijen RH, Vermorken JB
- Issue date: 1997 Dec
- Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer.
- Authors: Verborg WA, Campbell LR, Highley MS, Rankin EM
- Issue date: 2008 Mar-Apr